骨形态发生蛋白超说明书使用引发的医疗过失诉讼
该回顾性队列研究检索Westlaw与VerdictSearch数据库2000至2022年间医疗过失索赔,分析971例索赔中89例因骨形态发生蛋白(BMP)超说明书使用所致诉讼的特征与结局。结果发现后路入路最常见,30例指名外科医生为被告的病例中50%涉及知情同意不充分指控;最常见不良事件为异位骨形成导致慢性疼痛或神经损伤;无原告胜诉判决。作者认为理解BMP说明书使用范围(单节段、前路或前外侧入路、L2-S1、特定厂商 cage)有助于减少诉讼,并建议在知情同意中披露BMP使用(无论说明书内或外)。
要点
- 89例诉讼源于BMP超说明书使用,后路入路最常见。
- 30例外科医生被告中50%含知情同意不充分指控。
- 最常见不良事件为异位骨形成致慢性疼痛或神经损伤。
核心结论
- 明确BMP说明书使用范围为单节段、前路或前外侧入路、L2-S1、特定厂商cage,对减少医疗过失争议至关重要。
- BMP超说明书使用可能引发诉讼,但研究提示法院裁决对被告有利,无原告胜诉判决。
- 作者认为外科医生应权衡BMP超说明书使用的潜在获益与诉讼风险增加,并建议在知情同意中披露BMP使用(无论说明书内或外)。
研究设计与样本
- 回顾性队列研究,检索Westlaw与VerdictSearch数据库2000至2022年间医疗过失索赔,关键词为「bone graft」和「spine」。
- 纳入标准为原告诉讼依据为BMP超说明书使用导致的医疗过失。
- 共审查971例索赔,其中89例因BMP超说明书使用。
主要发现
- 89例中后路入路最常见。
- 30例指名外科医生为被告的病例中,50%包含知情同意不充分的指控。
- 最常见不良事件为异位骨形成导致慢性疼痛或神经损伤。
- 零例涉及异位骨化、伤口裂开、移植物下沉、血肿、尿潴留或逆行射精。
- 零例原告胜诉判决。
临床怎么用
- 作者认为外科医生应权衡BMP超说明书使用的潜在获益与诉讼风险增加。
- 作者建议在知情同意中披露BMP使用(无论说明书内或外)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To analyze the incidence and characteristics of malpractice lawsuits pertaining to the off-label use of Bone morphogenetic protein (BMP). SUMMARY OF BACKGROUND DATA: BMP continues to be a popular alternative to the use of autologous bone graft during spinal fusion procedures. However, ~85% of BMP is used in an off-label manner, which may expose surgeons to claims of malpractice. METHODS: Westlaw and VerdictSearch were queried for malpractice claims filed between 2000 and 2022 using the keywords "bone graft" and "spine." Case inclusion criteria were defined as a plaintiff's basis of litigation resting on a claim of medical malpractice due to off-label use of BMP. Additional collected data included the date of the case hearing, plaintiff's sex and age, defendants named in the lawsuit, verdict ruling, location of the filed claim, payment or settlement amount, sustained injuries, and additional allegations. RESULTS: Of 971 claims reviewed, 89 cases were due to off-label BMP use. The posterior approach was identified as the most common approach among the 89 cases. Of the 30 cases naming a surgeon defendant, 50% included allegations of insufficient informed consent. The most frequent adverse events were ectopic bone growth resulting in chronic pain or nerve damage. Zero cases involved heterotopic ossification, wound dehiscence, graft subsidence, hematoma, bladder retention, or retrograde ejaculation. CONCLUSION: A clear understanding that on-label BMP use is specific to single-level, anterior or anterolateral approaches between L2-S1 with vendor-specific cages is crucial for mitigating malpractice disputes. Though off-label use of BMP may incite litigation, the findings suggest court rulings are favorable for defendants as zero cases, resulting in plaintiff verdicts. Nevertheless, surgeons should balance the potential benefits of off-label use of BMP with the increased risk of litigation, and it may be advisable to disclose the use of BMP, whether on-label or off-label, in the informed consent.
引用
- Weldon E, Razzouk J, Bohen D, et al. Medical Malpractice Litigation Due to Off-Label Use of Bone Morphogenetic Protein. Spine (Phila Pa 1976). 2022. PMID: 36728790. doi:10.1097/BRS.0000000000004563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。